Do metformin a real anticarcinogen? A critical reappraisal of experimental data

Area of Science:

• Pharmacology
• Oncology
• Experimental Medicine

Background:

• Antidiabetic biguanides, such as phenformin, buformin, and metformin, are widely used for diabetes management.
• Emerging evidence suggests these compounds possess anticancer properties.

Purpose of the Study:

• To review and synthesize evidence on the cancer-preventive activity of antidiabetic biguanides in experimental settings.
• To analyze experimental design factors influencing biguanide efficacy in cancer prevention.

Main Methods:

• Comprehensive review of preclinical studies investigating antidiabetic biguanides for cancer prevention.
• Analysis of experimental parameters including study design, biguanide dosage, administration route, and animal age.

Main Results:

• Antidiabetic biguanides demonstrated efficacy in postponing spontaneous carcinogenesis in animal models.
• These drugs inhibited chemically, radiation, and biologically induced carcinogenesis across multiple organs and tissues.
• Evidence supports cancer-preventive activity in diverse mouse and rat strains.

Conclusions:

• Sufficient experimental evidence supports the cancer-preventive potential of antidiabetic biguanides.
• Further research into biguanide mechanisms and clinical applications for cancer prevention is warranted.